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ABSTRACT
Objective: To determine if adequacy of randomisation
and allocation concealment is associated with changes
in effect sizes (ES) when comparing physical therapy
(PT) trials with and without these methodological
characteristics.
Design: Meta-epidemiological study.
Participants: A random sample of randomised
controlled trials (RCTs) included in meta-analyses in
the PT discipline were identified.
Intervention: Data extraction including assessments
of random sequence generation and allocation
concealment was conducted independently by two
reviewers. To determine the association between
sequence generation, and allocation concealment and
ES, a two-level analysis was conducted using a meta-
meta-analytic approach.
Primary and secondary outcome measures:
association between random sequence generation and
allocation concealment and ES in PT trials.
Results: 393 trials included in 43 meta-analyses,
analysing 44 622 patients contributed to this study.
Adequate random sequence generation and appropriate
allocation concealment were accomplished in only
39.7% and 11.5% of PT trials, respectively. Although
trials with inappropriate allocation concealment tended
to have an overestimate treatment effect when
compared with trials with adequate concealment of
allocation, the difference was non-statistically
significant (ES=0.12; 95% CI −0.06 to 0.30). When
pooling our results with those of Nuesch et al, we
obtained a pooled statistically significant value
(ES=0.14; 95% CI 0.02 to 0.26). There was no
difference in ES in trials with appropriate or
inappropriate random sequence generation (ES=0.02;
95% CI −0.12 to 0.15).
Conclusions: Our results suggest that when evaluating
risk of bias of primary RCTs in PT area, systematic
reviewers and clinicians implementing research into
practice should pay attention to these biases since they
could exaggerate treatment effects. Systematic
reviewers should perform sensitivity analysis including
trials with low risk of bias in these domains as primary
analysis and/or in combination with less restrictive
analyses. Authors and editors should make sure that
allocation concealment and random sequence
generation are properly reported in trial reports.
INTRODUCTION
Randomisation and allocation concealment
have been extensively investigated in the
medical literature as key methodological
characteristics of randomised controlled
trials (RCTs) in medical research.1–3
Allocation concealment is the most com-
monly evaluated quality characteristic in
reviews of RCTs due to its crucial role as a
key marker of internal validity of RCT.4
Strengths and limitations of this study
▪ To the best of our knowledge, this is the first
meta-epidemiological study using continuous
outcomes in allied health disciplines such as
physical therapy (PT).
▪ This large meta-epidemiological study, which
was based on 43 Cochrane reviews, 393 trials
and 44 622 patients makes an important contri-
bution to the field.
▪ This study provides with novel evidence regarding
the association between adequacy of randomisa-
tion and allocation concealment and treatment
estimates in PT.
▪ We restricted our analysis to Cochrane system-
atic reviews in PT and results might not be
applicable to all Cochrane reviews or other
reviews conducted in other areas of research.
▪ For determining the association between random
sequence generation and allocation concealment,
we limited our analysis to trials describing a true
control group, or placebo intervention, reducing
our statistical power.
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Moreover, it is ﬁrmly established the conventional
wisdom that adequate randomisation sequence gener-
ation is an essential part of a valid clinical trial.5
There has been an extensive body of empirical research
looking at the inﬂuence of random sequence generation
and allocation concealment on treatment effect estimates
of health RCTs. Several meta-epidemiological studies
investigating the association between trial characteristics
and treatment effects have found an association between
inadequate randomisation and/or allocation conceal-
ment and an overestimation of treatment effects.1–3 6–9
For example, inadequate random sequence generation
can overestimate treatment effects by 12% (Ratio of ORs
(ROR) 0.88, 95% CI 0.79 to 0.99).10 Inadequate alloca-
tion concealment can overestimate treatment effects on
average by 18%.3 8 11 In addition, Pildal et al12 found that
2/3 of the conclusions from meta-analyses were no longer
supported if only trials with adequate allocation conceal-
ment were included and that 69% of meta-analyses
lost statistical signiﬁcance when trials with unclear or
inadequate allocation concealment were excluded.12
Over-estimates or underestimates of treatment effects can
lead to biased or inaccurate results and conclusions in sys-
tematic reviews and meta-analyses.3 12–15 These factors can
ultimately have repercussions on decision-making and
quality of patient care since different assessments could
lead to different decisions for clinical practice.
Most of the empirical evidence regarding the relation-
ship between trial components, and speciﬁcally random
sequence generation and allocation concealment, and
treatment effect estimates comes from RCTs in medicine
and is based mainly on dichotomous outcomes.3 8 11 No
such studies using continuous outcomes have been con-
ducted in other health areas such as the allied health pro-
fessions, including physical therapy (PT). Furthermore,
although it has been reported that the quality of
reporting of PT trials has improved over time,16 a ﬁner
analysis of types of random sequence generation and allo-
cation concealment in PT trials is lacking.
Therefore, it is necessary to determine the extent to
which sequence generation and allocation concealment
affect treatment effect estimates in PT trials to provide
accurate results to the PT clinical community. This infor-
mation is urgently needed to develop guidelines for
designing, conducting and implementing PT trials as well
as providing clear benchmarks to assess the quality and/or
risk of bias of PT trials in systematic reviews and
meta-analyses and ultimately the strength of evidence for
decision-making in PT. Therefore, our research questions
were: (1) are random sequence generation and allocation
concealment adequately used and reported in RCTs of PT;
(2) do random sequence generation and allocation con-
cealment have an effect on estimates of treatment in PT
trials; and (3) do effects sizes on PT trials differ depending
on some characteristics of the meta-analyses analysed such
as magnitude of the effect size, meta-analysis heterogen-
eity, type of outcome (subjective or objective) and whether
the meta-analysis involved the musculoskeletal area.
METHOD
Design
Meta-epidemiological approach.
Study selection
A random sample of RCTs included in meta-analyses in
the PT discipline were identiﬁed by searching the
Cochrane Database of Systematic Reviews from January
2005 to 25 May 2011 on PT interventions. The search
strategy can be found elsewhere and can be provided on
request.17 18 Meta-analyses were included if they met the
following eligibility criteria: (1) the meta-analysis included
at least three RCTs comparing at least two interventions,
with at least one of the interventions being part of PT
scope of practice according to the World Confederation
for Physical Therapy (WCPT);19 and (2) the main
outcome or the outcome of the meta-analysis with the
largest number of trials conducted in the review was
continuous.
Assessment of random sequence generation and
allocation concealment domains
Assessments of random sequence generation and alloca-
tion concealment domains were performed by two inde-
pendent reviewers following the Cochrane collaboration
guidelines.20
Random sequence generation assessment
In addition to the general evaluation of adequacy of
random sequence generation, different methods of
random sequence generation were determined. We
grouped these methods into four categories as follows:
Category 1 included trials where random sequence gener-
ation was unclear or not reported; category 2 included
trials that had adequate randomisation (eg, use of a
computer software, random number table and minimisa-
tion); category 3 included trials using acceptable methods
of randomisation, but less efﬁcient than the previous
category (eg, drawing lots, envelopes, shufﬂing cards,
throwing a dice); category 4 involved trials using inappro-
priate methods of sequence generation (eg, date of
birth, day of admission, hospital record number).
Categorisation into one of these four categories was con-
ducted in duplicate. To facilitate comparison with previ-
ous meta-analyses, these four categories were combined
to create two main groups: an “adequate sequence gen-
eration” group (combining categories 2 and 3) and an
“inadequate or unclear sequence generation” group
(combining categories 1 and 4).
Allocation concealment assessment
We divided the methods of allocation concealment used
in the trials into the following categories: Category 1 com-
prised trials that used any type of central randomisation
(eg, a remote telephone service or a central ofﬁce);
category 2 comprised trials that used sequentially num-
bered, opaque and sealed envelopes; category 3 com-
prised trials that used sealed envelopes without
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reporting any further details; and category 4 comprised
trials where allocation was clearly not hidden (eg, being
based on an open list, odd or even days of the week, par-
ticipant’s birth date or the team on duty at enrolment);
and category 5 comprised trials were concealment of allo-
cation was not reported or unclear. Categorisation into
one of these ﬁve categories was conducted by two inde-
pendent assessors. To facilitate comparison with previous
meta-analyses, these ﬁve categories were combined to
create two main groups: an “adequate concealment”
group (combining categories 1 and 2) and an “inad-
equate or unclear concealment” group (combining
categories 3, 4 and 5).
Data extraction of treatment estimates and trial
characteristics
Two independent reviewers extracted speciﬁc data (eg,
type of interventions, type of outcomes (ie, objective,
subjective), PT area) for all trials included in the
meta-analyses as well as data on means, SDs and sample
sizes. The primary outcome chosen for the analysis was
the main outcome of interest reported in the review or
determined from the meta-analysis that contained the
largest number of trials in the review. Details on the
reviewers’ panel and training process can be found
elsewhere.17 18
Data analysis
Data on sequence generation and allocation conceal-
ment were analysed descriptively based on the categories
described previously. In order to determine whether
random sequence generation and allocation conceal-
ment domains affect treatment effect estimates, a two-
level analysis was conducted using a meta-meta-analytic
approach with a random-effects model to allow for
within and between meta-analyses heterogeneity as sug-
gested by Sterne.21
The ﬁrst level analysis (within meta-analysis) was as
follows: we derived effect sizes (ES) for each trial by div-
iding the between-group difference in mean values by
the pooled SD.22 A negative ES indicates a beneﬁcial
effect of the experimental intervention. If some
required data were unavailable, we used approximations
as previously described.23 The data from each trial were
obtained from the meta-analyses included in our study.
We followed the classiﬁcation used in the Cochrane
reviews to classify the treatment arms as the experimen-
tal treatment of interest or as the control group. In the
case of studies appearing in more than one review, the
study was only considered once in the meta-analysis with
the fewer number of overall studies. We then calculated
two pooled ES for each meta-analysis: one correspond-
ing to the pooled effect size from studies having the
characteristic of interest (eg, allocation concealment)
and the other for studies that did not (eg, no or unclear
allocation concealment). We used standard random-
effects meta-analyses to combine ES across trials and cal-
culated the DerSimonian and Laird estimate of the
variance to determine heterogeneity between trials.1 24
Then, for each meta-analysis, we derived the difference
between pooled ES estimates from trials with and
without the characteristic of interest (eg, allocation con-
cealment). A negative difference in ES indicates that
trials without the characteristic of interest show a more
beneﬁcial effect for the experimental group.
The second level analysis (between meta-analyses)
involved pooling the results of the previous analysis to
describe the effect of each trial component across all
meta-analyses. The ES were also combined at this stage
using the DerSimonian and Laird random-effects
models25 to allow for between meta-analysis heterogeneity.
Formal tests of interaction between adequate sequence
generation and concealment of allocation and estimated
treatment beneﬁts were performed separately for each
meta-analysis based on Z scores using the estimated dif-
ference in ES between trials with and without adequate
sequence and concealment of allocation and the corre-
sponding SE.
We additionally stratiﬁed analyses accompanied by
interaction tests according to the prespeciﬁed character-
istics as reported by Nuesch et al1 as follows: treatment
beneﬁt in overall meta-analysis: small (ES greater than
−0.5) versus large (ES≤ to −0.5); between-trial hetero-
geneity in overall meta-analysis (low (τ2<0.06) vs high
(τ2≥0.06)), nature of the outcome (subjective or object-
ive) and if the intervention was classiﬁed as musculoskel-
etal or other PT area.
In order to evaluate the effect of random sequence
generation and allocation concealment on treatment
effect estimates, we limited the analyses to studies
describing a true control group, or placebo intervention
as well as studies in which the direction of the expected
treatment effect was evident (ie, standard care vs stand-
ard care plus active intervention; and active intervention
1 plus active intervention 2 vs active intervention 1).
Finally, results of our analyses were pooled with results
from the meta-epidemiological study performed by
Nuesch et al,1 which also investigated the effect of con-
cealment of allocation on treatment effects on osteoarth-
ritis measured on a continuous scale. Stata statistical
software V.12 was used to perform these analyses.
RESULTS
Selection and characteristics of meta-analyses and RCTs
The search identiﬁed 3901 Cochrane reviews, with 271
reviews potentially relevant to PT. Of these, 68 reviews
included a meta-analysis of at least three studies of PT
interventions and used a continuous outcome. We ran-
domly selected 44 meta-analyses but excluded one 26
because it used follow-up data from the same group
rather than a control group for comparison (ﬁgure 1).
Forty-three meta-analyses including 393 trials and analys-
ing 44 622 patients contributed to this study. Table 1
summarises the characteristics of the 43 Cochrane
reviews. Brieﬂy, the reviews were published between
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2008 and 2011 and included meta-analyses of the effect-
iveness of PT interventions for musculoskeletal
(22 reviews),27–35 cardiorespiratory (9 reviews),36–44
neurological (6 reviews)45–51 and other areas of physical
therapy (6 reviews).51–56 A median number of six trials
were included in the meta-analyses (IQR 5–8). Most
trials were parallel group trials (367; 93.4%), single-
centre studies (298; 76%) and had active control inter-
ventions (362; 92%). The most common intervention
was exercise (n=282, 71.8%). Online Supplementary
table S1 (appendix S1) lists the characteristics of each of
the 43 meta-analyses.
Sequence generation descriptive
From the 393 trials included in the 43 meta-analyses,
156 trials (39.7%) had appropriate sequence generation
and 237 (60.3%) had inappropriate sequence gener-
ation (229 were classiﬁed as ‘unclear’ and 8 as ‘high’
risk of bias) according to the Cochrane Collaboration
guidelines.
When analysing the sequence generation categories,
we found that 229 trials (58.27%) did not clearly report
the mechanism of how the sequence was generated.
One hundred and thirty-two trials (33.6%) generated
the sequence through computer software, a table of
random numbers or by minimisation method. For a
more speciﬁc sequence generation methods description,
see table 2.
In addition, simple randomisation was reported in 34
trials, block randomisation in 54 trials, stratiﬁcation in
62 trials and unclear or not reported in 218 trials. The
rest of the trials reported other methods of random
sequence generation.
Allocation concealment descriptive
From the 43 meta-analysis and 393 trials, 45 trials
(11.5%) had appropriate allocation concealment and
348 (88.6%) had inappropriate concealment of alloca-
tion according to the Cochrane Collaboration guide-
lines. Results of analysis of the allocation concealment
within each category were as follows: 282 trials (71.8%)
had unclear method of allocation concealment, 21
(5.34%) trials used central allocation, 24 (6.11%) trials
used envelopes with all 3 safe wards (opaque, sealed and
Figure 1 Diagram for
identification of studies.
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sequentially numbered), 15 (3.82%) trials used envel-
opes without safeguards and 51 (16.8%) trials used any
other non-concealed methods. Further details on alloca-
tion concealment methods are displayed in table 3.
Sequence generation and allocation concealment
descriptive
Only 8.9% of the trials (n=35) had both appropriate
sequence generation and appropriate allocation conceal-
ment. A great percentage (51%; n=199) of the trials did
not have either appropriate sequence generation or
appropriate concealment of allocation.
Sequence generation and treatment effects in PT trials
For the purpose of analysing the effect of sequence gene-
ration on treatment effects, 22 meta-analyses including
257 trials and analysing 30 287 patients contributed to
this analysis. Figure 2 shows the forest plot of the differ-
ences in ES between trials with adequate and inadequate
random sequence generation. There was no statistically
signiﬁcant difference between the ES of trials with
adequate or inadequate random sequence generation
(ES=0.02; 95% CI −0.12 to 0.15). The results of the strati-
ﬁed analyses are displayed in ﬁgure 3. None of the
meta-analyses characteristics had a statistically signiﬁcant
interaction.
When analysing trials belonging only to category 2
which included trials that had adequate sequence gener-
ation (eg, use of a computer software, random number
table and minimisation) versus unclear or not reported
sequence generation, no statistically signiﬁcant differ-
ence between the ES of these trials was found (ES=0.10;
95% CI −0.04 to 0.23). However, trials with unclear or
not reported sequence generation tended to overesti-
mate the treatment effect when compared with trials
with adequate sequence generation from category 2.
It was not possible to conduct the subgroup analysis
between trials of category 2 versus trials from category 4
(using inappropriate methods to perform sequence gen-
eration such as date of birth, day of admission, hospital
record number) since there were not enough trials for
such analysis.
Table 1 Characteristics of the selected meta-analysis within physical therapy areas
Musculoskeletal Cardio respiratory Neurology Other
Characteristics
Number of meta-analyses 22 9 6 6
Median year of publication 2009 2010 2009 2009
Total number of trials included 194 78 52 69
Total number of patients included 19 861 9015 2138 13 608
Main intervention
Exercise 13 7 3 5
Physical agents 1 0 1 0
Acupuncture 2 0 0 0
Manual therapy 1 0 0 0
Other 1 2 2 1
Outcomes
Clinician-assessed outcome 8 4 6 3
Self-reported outcome 11 4 0 2
Administrative data or automated outcome 3 1 0 1
Table 2 Methods of sequence generation in physical
therapy trials
Sequence generation methods Number of trials (%)
Unclear/not reported 232 (59.03)
Computer software 65 (16.54)
Random number table 60 (13.49)
Drawing of lots 12 (3.05)
Shuffling cards or envelopes 9 (2.29)
Minimisation 6 (1.52)
Other non-random methods 4 (4.33)
Coin tossing 1 (0.25)
Date of birth 1 (0.25)
Day of admission 1 (0.25)
Hospital/institution records number 1 (0.25)
Throwing a dice 1 (0.25)
Total 393 (100)
Table 3 Methods of allocation concealment in physical
therapy trials
Allocation concealment methods
Number of trials
(%)
Unclear/not reported 282 (71.76)
Central concealment 21 (5.34)
Sequentially numbered, opaque and
sealed envelopes
24 (6.11)
Unsafe envelopes 15 (3.82)
Non-safe methods of allocation 51 (12.98)
Total 393 (100)
Armijo-Olivo S, et al. BMJ Open 2015;5:e008562. doi:10.1136/bmjopen-2015-008562 5
Open Access
group.bmj.com on November 5, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
Allocation concealment and treatment effects in PT trials
For the purpose of analysing the effect of allocation con-
cealment on treatment effects, 17 meta-analyses includ-
ing 198 trials and analysing 27 011 patients contributed
to this analysis. Figure 4 shows the forest plot of the dif-
ferences in ES between trial with adequate and inad-
equate allocation concealment. Although trials with
inappropriate allocation concealment tended to have an
overestimate treatment effect when compared with trials
with adequate concealment of allocation, the difference
was non-statistically signiﬁcant (ES=0.12; 95% CI −0.06
to 0.30). The results of the stratiﬁed analyses are dis-
played in ﬁgure 5. None of the meta-analyses character-
istics had a statistically signiﬁcant interaction. When
Figure 2 Forest plot of the differences in effect sizes between trials with and without adequate sequence generation.
Figure 3 Forest plot of the differences in effect sizes between trials with and without sequence generation stratified by
meta-analyses characteristics (effect size magnitude, heterogeneity, type outcome and physical therapy area).
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focusing on trials with appropriate allocation conceal-
ment (category 1 and 2) versus trials with clearly
inappropriate methods of concealment (category 4), the
difference was not statistically signiﬁcant (ES=0.26; 95%
CI −0.04 to 0.55). However, trials with clearly inappro-
priate methods of concealment (category 4) tended to
overestimate the treatment effects. The same was the
case when comparing the trials with appropriate alloca-
tion concealment (category 1 and 2) versus trials with
unclear or unreported concealment of allocation
(ES=0.20; 95% CI 0.05 to 0.34). This time, the difference
between these trials was statistically signiﬁcant.
Pooling results with a previous meta-epidemiological
study
When pooling our results with those of Nuesch et al,1
who performed a meta-epidemiological study with con-
tinuous outcomes as well, we obtained a pooled statistic-
ally signiﬁcant value (ES=0.14; 95% CI 0.02 to 0.26),
meaning that trials with inappropriate concealment of
allocation had more beneﬁcial effect than trials with
appropriate concealment of allocation (ﬁgure 6).
DISCUSSION
Our ﬁndings showed that adequate sequence generation
and appropriate allocation concealment were only
accomplished in a low percentage of PT trials (39.7%
and 11.5%, respectively). In addition only 8.9% of the
trials (n=35) had both appropriate sequence generation
and appropriate allocation concealment despite the fact
that both of the aforementioned risk of bias domains
can be always appropriately performed when conducting
an RCT in any ﬁeld.57 In addition, trials with inappropri-
ate concealment of allocation had an overestimation of
treatment effects when compared with trials with
adequate concealment of allocation. However, no differ-
ence in treatment effects in trials with appropriate or
inappropriate sequence generation was found. These
results conﬁrm previous results obtained by several
meta-epidemiological studies investigating the inﬂuence
of sequence generation and allocation concealment on
several areas of medicine using dichotomous out-
comes.7 8 11 12 58 In addition, the pooled estimate
obtained from our study and that of Nuesch et al,1 indi-
cated that trials with inappropriate allocation conceal-
ment had a more beneﬁcial effect than those with
appropriate allocation concealment.
These results have important implications for the
research community in general as well as for the discip-
line of PT. To our knowledge; this study is the ﬁrst of its
kind conducted in PT that examined continuous out-
comes. Thus, it provides novel evidence in a very speciﬁc
area of health. Most of the previous studies were looking
at medical areas, such as pregnancy and childbirth, cir-
culatory conditions, infectious disease, surgery and
mental health trials. All of these medical areas certainly
differ from PT with respect to: type of intervention
(being mostly drugs), type of outcomes used and spe-
ciﬁc area of study.
Figure 4 Forest plot of the differences in effect sizes between trials with and without adequate concealment of allocation.
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First, it is not surprising that a large number of trials
did not clearly report either randomisation sequence or
allocation concealment or both. Our ﬁndings showed
that approximately 62% and 70% of studies were classi-
ﬁed as ‘unclear/not reported’ in their reporting of
sequence generation and allocation concealment,
respectively. This has also been observed in a
meta-epidemiological study investigating meta-analyses
before 2005.2 The study found a 64% and 69% of
‘unclear’ reporting of sequence generation and alloca-
tion concealment, respectively.2 Thus, despite the efforts
made to improve reporting of RCTs such as introducing
the CONSORT Statement, there is still inappropriate
reporting and implementation of these important
characteristics in RCTs. This is in agreement with results
reported by Moseley et al,16 who found little or no effect
of the CONSORT Statement on the quality of reports of
physiotherapy trials. Quality of reporting has always been
an issue when trying to understand the association
between trial characteristics and treatments effects since
most of authors do not properly report their methods.
Although inappropriate reporting does not always
reﬂect on weak trial conduct,59 some studies such as
Pildal et al,12 found that most trials with unclear alloca-
tion concealment had also unclear allocation conceal-
ment in their protocol. Therefore, quality of reporting is
Figure 5 Forest plot of the differences in effect sizes between trials with and without adequate concealment of allocation
stratified by meta-analyses characteristics (effect size magnitude, heterogeneity, type outcome and physical therapy area).
Figure 6 Pooled data of the effect of concealment of allocation on treatment effect estimates using continuous outcomes.
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related to assessment of risk of bias, but the direction of
this relationship is still unclear. Future studies should
assess how, how much and in which direction trial
reporting affects treatment effects.
The magnitude and direction of the effect found in
our study is consistent and almost identical with a previ-
ously published study performed in osteoarthritic trials
investigating allocation concealment. In our study, the
average bias associated with lack of allocation conceal-
ment corresponds to ¼ or ½ of a typical treatment effect
found in PT interventions.60–63 Furthermore, the over-
estimation of a treatment effect was even higher when
only focusing the analysis to trials with clearly inappro-
priate methods of allocation concealment. As stated by
others,2 8 if allocation concealment is not accomplished,
it is more likely that the results of the trial are inaccurate
because, intentionally or unintentionally, investigators
could have interfered with assigning participants to dif-
ferent groups, favouring the effect of the intervention.
In addition, allocation concealment could be a proxy
measure for other aspects of trial design besides selec-
tion bias.2 8
Random sequence generation was found not to be sig-
niﬁcantly associated with distortion of treatment effects
in this study. Thus, it appears that random sequence
generation does not have such a strong inﬂuence on
treatment effects in comparison with concealment of
allocation based on the results of the present study.
Other meta-epidemiological studies have found similar
results. 8 11 64 One of these studies, performed by Balk
et al,64 has been questioned because of the high hetero-
geneity between trials included in meta-analysis. This
could introduce a higher noise to be able to detect any
effect of the trials characteristics. The other studies
reported the same results argue that sequence gener-
ation is still an important characteristic that ensures
rigour in the trial by allowing a trial to be concealed.8 11
In addition, other authors have suggested that the rela-
tionship between certain methodological characteristics
and treatment effects varies according to each health
area64 65 and more work should be carried out in other
health areas to conﬁrm these results.64 65
Our stratiﬁed analysis for sequence generation and
allocation concealment showed that none of the
meta-analysis characteristics presented with signiﬁcant
interaction. This is somehow contrary to other
meta-epidemiological studies. For example, Wood et al,3
and Savovic et al,2 found that there was an overestimation
of treatment effects that ranged between 22% and 31%
for subjective outcomes. We followed exactly the same
deﬁnition for determining outcomes as ‘objective and
subjective’ used by Wood et al,3 to facilitate comparisons
and avoid misclassiﬁcations. Thus, it seems that for PT
area, there is no evidence of bias regarding random
sequence generation or allocation concealment when
subjective or objective outcome are used. This could be
attributed to the fact that both domains can be per-
formed in a trial regardless of the outcome analysed.
Thus, whether the outcome is objective or subjective
does not affect whether it is easier or not to predict
patient’s prognosis at the time of recruitment.
Study limitations
We analysed the inﬂuence of random sequence gener-
ation and allocation concealment on treatment effect
estimates. It could be possible that other biases interact
with these biases and have an inﬂuence in the treatment
effects. This should include a multivariate analysis where
several biases should be taken into consideration. Future
research should look into this. However, such analysis
would require meta-analyses with a large number of
included studies, which are extremely rare; this makes
such an analysis hard to be performed.
We limited our analysis to trials describing a true
control group (ie, group receiving no treatment, or a
waiting list), or placebo intervention as well as those
studies in which the direction of expected treatment
effect was evident. In this way, we could anticipate the
direction of the bias in analyses. Combining effects of all
trials without clear direction of what would be the effect
(ie, in case of 2 similar active interventions) would have
increased noise in the analyses and heterogeneity limit-
ing our ability to ﬁnd any signiﬁcant effect of trials
characteristics.66 However, limiting our analyses to these
trials, we also reduced the power of our study.
CONCLUSIONS
Trials with inappropriate concealment of allocation had
an overestimation of treatment effects when compared
with trials with adequate concealment of allocation. Our
results suggest that when evaluating risk of bias of
primary RCTs in PT area, systematic reviewers and
clinicians implementing trial ﬁndings into their clinical
practice should pay attention to these characteristics,
especially allocation concealment since it can be
associated with an exaggeration of a treatment effect.
Systematic reviewers should perform sensitivity analysis
including trials with low risk of bias in these domains as
primary analysis and/or in combination with less restrict-
ive analyses. In addition, appropriate methods of
sequence generation as well as allocation concealment
should be implemented. Authors and editors should
make sure that allocation concealment and random
sequence generation are properly reported in trial
reports.
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